Aaron Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, highlights the exciting updates in myeloproliferative neoplasms (MPNs) presented at ASH 2020. We saw encouraging data from both the MANIFEST and MOMENTUM studies, with increased response rates and reduced symptom burden being reported. Two novel agents, imetelstat and PTG-300 have also shown impressive results in myelofibrosis (MF) and polycythemia vera (PV) patients respectively. Many of the treatments discussed at ASH 2020 are now entering Phase III and it will be interesting to see the data from these stages at next year’s meeting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Aaron Gerds, MD, MS, has served on advisory boards for Galecto, PharmaEssentia and Constellation.